Skip to content

Safety evaluation of overdose intake of foods containing Lactobacillus brevis subsp. coagulans (Labre)

Safety evaluation of overdose intake of foods containing Lactobacillus brevis subsp. coagulans (Labre) - Safety evaluation of overdose intake of foods containing Lactobacillus brevis subsp. coagulans (Labre)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000052722
Enrollment
20
Registered
2023-11-08
Start date
2023-11-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Test food: Food containing Labre

Sponsors

Medical Corporation Hokubukai Utsukushigaoka Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Healthy Japanese males and females between 20 and 65 years of age, or Japanese males and females with constipation tendency (defecation frequency less than 4 times/week) (2) Subjects who can be available at the research site on the designated dates (3) Subjects who have received sufficient explanations about the purpose and content of this study, have the ability to consent, volunteer to participate in this study in writing with a good understanding.

Exclusion criteria

Exclusion criteria: (1) Subjects who have a history of heart, liver, kidney disease, organ damage, diabetes, or other serious diseases (2) Subjects who have a history of gastrointestinal surgery (excluding appendectomy) (3) Subjects who are currently receiving medical drug treatment (4) Subjects who are pregnant, wish to become pregnant during the study, or are breastfeeding (5) Subjects who take foods or supplements containing lactobacilli or bifidobacteria 3 times or more a week (Suguki pickle, bran pickle, kimchi, "Labre capsules", etc.) (6) Shift workers, including late-night shifts (7) Subjects who drink more than 60 g pure alcohol equivalent/day on average (8) Subjects who smoke an average of 21 cigarettes or more per day (9) Subjects who donated blood within 3 months at screening (10) Subjects who are participating in clinical research or monitoring (food, pharmaceuticals, cosmetics) other than this research, or plan to participate during this research period (11) Subjects who are judged to be inappropriate for this study with other reasons by the principal investigator.

Design outcomes

Primary

MeasureTime frame
Change of the values of physical test, hematological test, blood biochemistry test and urinalysis, and the number of adverse events

Countries

Japan

Contacts

Public ContactTakuya Matsuda

Medical Corporation Hokubukai Utsukushigaoka Hospital Clinical Pharmacology Center

matsuda@ughp-cpc.jp011-882-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026